News Quantified

KNSA – kiniksa pharmaceuticals, ltd. - class a (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Kiniksa Pharmaceuticals International (KNSA) was upgraded by Zacks Research from "strong sell" to "hold".

Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility [Yahoo! Finance]

Kiniksa Pharmaceuticals, Ltd. Q4 2025 Earnings Call Summary [Yahoo! Finance]

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wells Fargo & Company from $50.00 to $53.00. They now have an "overweight" rating on the stock.

-4.4%

MISS

-7.5%

MISS

11.4%

BEAT

15.0%

BEAT

Canaccord Genuity

Form 4 Kiniksa Pharmaceuticals For: Mar 02 Filed by: Paolini John F.

Form 144 Kiniksa Pharmaceuticals Filed by: Paolini John F.

Form S-8 Kiniksa Pharmaceuticals

Form 10-K Kiniksa Pharmaceuticals For: Dec 31

Form 8-K Kiniksa Pharmaceuticals For: Feb 24

Top News Gainers

11/20 Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis 28.7%

3/31 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation 26.7%

12/10 Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 18.5%

10/28 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus N/A ActVsEst N/A - N/A 11.8%

8/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 6.2%

3/17 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 5.7%

6/7 Form SC 13D/A Kiniksa Pharmaceuticals, Filed by: BAKER BROS. ADVISORS LP 4.4%

3/20 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.2%

8/19 Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 4.0%

1/13 Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts 3.6%

Top News Decliners

3/17 Form 4 Kiniksa Pharmaceuticals, For: Mar 13 Filed by: Paolini John F. -16.6%

3/10 Form 4 Kiniksa Pharmaceuticals, For: Mar 06 Filed by: Patel Sanj K -10.4%

11/5 Form 10-Q Kiniksa Pharmaceuticals, For: Sep 30 -8.4%

6/11 Form EFFECT Kiniksa Pharmaceuticals, -8.1%

4/22 Form 4 Kiniksa Pharmaceuticals, For: Apr 20 Filed by: Beetham Thomas W. -7.1%

4/29 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.2%

2/14 Form SC 13G Kiniksa Pharmaceuticals, Filed by: AMERIPRISE FINANCIAL INC -5.6%

7/11 Form D/A Kiniksa Pharmaceuticals, -5.2%

4/1 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a $25.00 price target on the stock. -5.2%

10/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day